|
|
![]() | ![]() | ![]() | ![]() |
This excerpt taken from the AZN 6-K filed Jun 2, 2006. Information relating to AstraZeneca and AstraZeneca PLC AstraZeneca is engaged in the research, development, manufacture and marketing of prescription pharmaceuticals, focusing on gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is a wholly-owned subsidiary of AstraZeneca PLC and the principal UK trading entity in the AstraZeneca PLC group. For the fiscal year ended 31 December 2004 and prepared in accordance with UK Accounting Standards, AstraZeneca had turnover of approximately £3.3 billion, profit before tax of approximately £0.7 billion and net assets of approximately £5.2 billion. AstraZeneca PLC is a major international healthcare business and is one of the world's leading pharmaceutical companies with a market capitalisation of £45.1 billion. For the fiscal year ended 31 December 2005 and prepared in accordance with International Financial Reporting Standards (IFRS), AstraZeneca PLC had revenues of approximately $23.95 billion and profit before tax of approximately $6.67 billion. AstraZeneca PLC is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. |
| |||||||